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ORIGINAL RESEARCH
Sustained release of acyclovir from nano-liposomes 
and nano-niosomes:  An in vitro study 
Abstract: The present study was designed to develop and compare acyclovir containing 
nano-vesicular liposomes and niosomes based on cholesterol, soya L-α-lecithin and nonionic 
surfactant, span 20. The effort was made to study in vitro whether acyclovir-loaded nanovesicles 
could sustain the release of the drug by increasing residence time and thus, acyclovir could 
reduce its dose-related systemic toxicity. There were good vesicular distributions in both of 
the niosomes and the liposomes. The obtained vesicles were within 1 μm and about 35% of 
them were within a size of 100 nm. The percentage of drug loading varied and the niosomal 
vesicles contained more drug as compared with the liposomes. When the in vitro drug release 
was compared, it was found that the liposomes released about 90% drug in 150 min whereas 
the drug release was just 50% from the niosomal vesicles in 200 min. Again, the niosomes 
showed better stability compared with the liposomes. Thus, niosome could be a better choice 
for intravenous delivery of acyclovir.
Keywords: acyclovir, liposomes, niosomes, sustained release
Introduction
Liposomes are the unilamellar or multilamellar spherical structures consisting of lipid 
bilayers arranged in a concentric fashion enclosing an equal number of aqueous com-
partments (Fang et al 2001; Chetoni et al 2004; Pavelic et al 2005). On the other hand 
niosomes or nonionic surfactant vesicles are similar to liposomes and they specially 
contain nonionic surfactant molecules (Fang et al 2001). These are able to encapsulate 
both hydrophilic and lipophilic molecules. Moreoften, niosomes are preferred as a drug 
carrier to liposomes because of their advantages related to stability, low cost, and usage 
of variable purities in their manufacturing with phospholipids (Fang et al 2001). 
Acyclovir, an analogue of 2/- deoxyguanosine, has been known for its antiviral 
activity against varicella zoster virus, Epstein barr virus, cytomegallo virus, herpes 
simplex virus (HSV), and human herpes virus 6 (Wagstaff et al 1994; Hayden1996). 
The oral bioavailability of acyclovir is poor (15%–20%) requiring frequent dosing 
regimen (Thummel and Shen 2001). Its limited solubility in water makes its intra-
muscular administration rather difﬁ  cult (Freeman et al 1986). Many researchers have 
tried to increase its solubility by modifying chemical structure or by prodrug approach 
(Bundgared et al 1991; Shao et al 1994; Chikhale et al 1996). But none of the ﬁ  ndings 
are very encouraging. When administered intravenously, most of acyclovir is excreted 
unchanged through urine since the drug molecules are excreted through kidneys by 
both glomerular ﬁ  ltration and tubular secretion. The intravenous administration of 
acyclovir sodium results in thrombophlebitis and has chances of drug crystal forma-
tion when excreted through kidneys during the systemic treatment of HSV infections 
in immuno-competent as well as immuno-compromised patients (Brown et al 2002). 
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The terminal or beta-phase half-life of acyclovir is reported 
to be 2 to 3 h for adults (Thummel and Shen 2001). Thus, 
the dose of the drug is high and residence time of the drug 
in circulation is very less.
So the aim of our research was to develop stable nano-
liposomal and nano-niosomal vesicles of acyclovir, which 
can remain in systemic circulation for a longer time and thus 
the dose-related toxicities may be reduced (Jain et al 2005). 
The study was conducted using in vitro methods only.
Methodology
Preparation of liposomes and niosomes
Liposomes and niosomes were prepared by lipid layer 
hydration method. Brieﬂ  y, the weighed amounts of soya 
lecithin, span 20, polyethylene glycol 400 (PEG 400), 
and cholesterol as per their experimental combinations 
(Table 1) containing butylated hydroxyanisole (BHA) (2% 
w/w of lipid) wherever necessary were taken in 250 ml 
round bottom ﬂ  ask and were dissolved in chloroform by 
hand-shaking. The mixture was placed in a rotary vacuum 
evaporator with an aspirator A 3S (Tokyo Rikakikai Co. 
Ltd., Tokyo, Japan). The rotary vacuum evaporator was 
ﬁ  tted with a cold water circulating bath (Spac-N Service, 
Kolkata, India) and was rotated at 150 rpm. The temperature 
of the water bath was maintained at 32 °C to evaporate the 
solvent. After the initial evaporation, the ﬂ  ask was kept 
in a vacuum desiccator overnight for complete removal 
of residual chloroform. Acyclovir (1.66 mg/ml) was dis-
solved in phosphate buffer (pH 7.4) and the desired volume 
was then taken into a ﬂ  ask containing lipid ﬁ  lm. The ﬁ  lm 
was hydrated in a rotary vacuum evaporator maintained at 
60 °C and rotated at 100 rpm until the lipid ﬁ  lm was dis-
persed in the aqueous phase. The sizes of the vesicles were 
reduced by a bath-sonicator (30 ± 2 KHz) (Instrumentation 
India, Kolkata, India) at 60 °C for 1 h. After sonication, 
the preparations were kept at room temperature for 1 h 
for vesicle formation and then they were kept at 4 °C in 
an inert atmosphere for 24 h. The preparations were then 
centrifuged at 5000 rpm at 4 °C for 5 min. The supernatant 
containing the vesicles in each case was taken for further 
studies as a suspended formulation. The formulations were 
also lyophilized with a cryo-protectant, sucrose, in different 
sucrose to lipid wt. ratio (1:1 and 2.5:1). The lyophilization 
was done using a lyophilizer (Instrumentation India ltd, 
Kolkata, India). Primary drying was conducted at –35 °C 
for 8 h under vacuum after the standard prefreezing. 
Stability study of liposomes 
and niosomes containing acyclovir
The stability study was conducted to monitor physical and 
chemical stabilities of the lyophilized forms as well as the 
reconstituted lyophilized forms. The stability parameters 
such as vesicular fusion, variation in pH, size distribution, 
drug-excipient interaction, and lipid degradation in terms of 
lipid peroxidation were determined. 
The resuspended (reconstituted) lyophilized and lyophi-
lized formulations of liposomes and niosomes were stored 
at 25 °C (±1 °C), 4 °C (±1 °C), and –20 °C (±1 °C) for three 
months. Then the above mentioned various parameters 
were studied. In case of the formulations underwent fusion 
detected by light microscope and degradation in terms of 
cracking (visible) of the formulations, no further study was 
conducted with them. 
Morphology
Morphology of the vesicles was performed with the help of 
scanning electron microscope (SEM) (JSM, JEOL, Tokyo, 
Japan). Fusions and crystallization were detected by optical 
microscopy.
pH measurement
pH was measured using a pH meter (Sigma, Toledo, USA) 
at 25 ± 0.5 °C. Both the reconstituted lyophilized forms and 
the lyophilized forms stored at various temperatures were 
studied (but not degraded ones) for pH. 
Size distribution and zeta potential
Size distribution and zeta potential measurement was 
performed with the help of Zetasizer nano ZS (Malvern 
Instruments Ltd., UK). The image was processed in a Metlab 
environment (METLAB-7.0). The threshold image was 
subjected to object analysis using a NIH imaging software 
Table 1 Constituents of various formulations containg acyclovir
Formulation  Compositions in  % drug load
codea  ratio(μmole)  (mean ± SE, n = 3)
L1  bSPC:CH = 131.57:28.71   8.52 ± 2.11
L2  bSPC:CH = 131.57:12.82  6.49 ± 2.31
L3  bSPC:CH:PEG 400 =   8.61 ± 1.31
 131.57:  28.71:84.37
N1  bSPC:CH:Span20 =   28.9 ± 3.53
 131.57:28.71:44.48
N2  Span 20:CH = 75:75   20.02 ± 5.21
N3  Span 20: CH = 100:50  14.01 ± 3.34
N4  Span 20:CH:PEG  9.28 ± 2.31
  400 = 75:75:84 
Note: aEach formulation contained 22.2 μmole of acyclovir; bSPC, Soya L-α-
Lecithin; CH, cholesterol.International Journal of Nanomedicine 2007:2(2) 215
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(image tools). The classiﬁ  ed objects were then subjected to 
histogram analysis.
Lipid peroxidation (LP) study
LP was measured of all the freshly prepared formulations 
and of those found stable after storage at different tempera-
tures. The data were given for the stable formulations only 
along with the corresponding fresh ones. The extent of lipid 
peroxidation was assessed from the amount of thiobarbituric 
acid (TBA) reactive substances produced which was spec-
trophotometrically read at 532 nm as mentioned (Gallova 
and Szalayova 2004).
Fourier transform, infrared (FTIR) study
The pure drug acyclovir, cholesterol, soya lecithin, and a 
mixture of drug with cholesterol, and soya lecithin were 
mixed separately with infrared (IR) grade KBr in the ratio of 
100:1 and corresponding pellets were prepared by applying 
5.5 metric tons of pressure in a hydraulic press. The pellets 
were scanned in an inert atmosphere over a wave number 
range of 4000–400 cm–1 in Magna IR 750 series II (Nicolet, 
USA) FTIR instrument.
In case of the lyophilized formulations, FTIR study was 
done using the same method mentioned above. In case of the 
other formulations, after centrifugation the precipitate was 
taken and a thin ﬁ  lm of it was made in between two discs 
and placed inside the sample holder.
Drug loading study
Reconstituted lyophilized formulations and the freshly 
prepared suspensions were undergone centrifugation 
(Fixed angle ultracentrifuge, 54 k = Avg. RCF = 20, 3300 
xg = 54200, Sorvall, USA, run for 8 h) to precipitate lipo-
somes and niosomes. Drug loading estimation was done by 
simple extraction of drug with 0.1(N) hydrochloric acid from 
chloroform by breaking the vesicle layers with chloroform. 
The extract was diluted with 0.1(N) hydrochloric acid and 
absorbance was measured at 254.5 nm using UV/VIS spec-
trophotometer (Beckman, USA) against 0.1(N) hydrochloric 
acid as blank. The same procedure was used for the batch 
without drug. The absorbance due to drug was the difference 
between the readings obtained from the respective prepara-
tions with drug and without drug. The drug content was then 
determined from the standard curve. 
In vitro release study
In vitro release of acyclovir from niosomes and liposomes 
was conducted by dialysis in a dialysis sac (Sigma, 12000 
MW cut off) with 180 ml of phosphate buffer saline (PBS) 
buffer at 37 °C following the method published elsewhere 
(Zhang et al 2005). In a 250 ml conical ﬂ  ask, 180 ml of PBS 
was taken. 1 ml (250 mg freeze-dried formulation/ml) of a 
formulation was taken into a dialysis bag. Two ends of the 
dialysis sac were tightly bound with threads. The sac was 
hanged inside a conical ﬂ  ask with the help of a glass rod 
so that the portion of the dialysis sac with the formulation 
should dip into the buffer solution. The ﬂ  ask was kept on a 
magnetic stirrer. Stirring was maintained at 300 rpm with the 
help of a magnetic bead and the temperature of the water was 
maintained at 37 °C with a thermostatic control. Sampling 
was done by withdrawing 1 ml from the released medium 
with the help of micropipette and 1 ml of fresh buffer was 
added. Samples were analyzed using a spectrophotometer 
at a wave length of 252 nm. With the help of the standard 
curve prepared earlier, drug concentration was measured. 
In case of the freeze-dried formulations, reconstitution was 
done with PBS buffer just before putting into a dialysis bag 
for release study.
Results
The prepared liposomes and niosomes were lyophilized 
with a cryo-protectant, sucrose, in different sucrose to lipid 
wt. ratio (1:1 and 2.5:1). The formulations containing lipid 
sucrose ratio 1:1 showed sedimentation, drug crystal for-
mation as well as vesicular fusion (Figure 1). So they were 
not considered for further study. It was observed that the 
lyophilized formulations at the sucrose-lipid ratio of 2.5:1 
were easily redispersed (when reconstituted) in PBS buffer 
without any sediment or drug crystals. There was also a good 
distribution of vesicles. Hence, further study was conducted 
with those formulations. 
After three months of the stability study, it was observed 
that the formulations both in liquid and lyophilized states 
became unstable at 25 ± 1 °C and at 4 °C (except niosomes). 
At 4 °C, the lyophilized-niosomes were found to be stable. 
All the formulations were stable at –20 °C.
Both the reconstituted lyophilized forms and the lyophi-
lized forms stored at the different temperatures were studied 
for pH (but not the degraded ones). The formulations kept 
at 25 °C and 4 °C (except the lyophilized niosomes) were 
found to be degraded and they were not studied further. 
There was no major change in pH of the formulations. 
The pH values (data show mean ± SD, n is the number 
of experiments) of the lyophilized and the reconstituted 
lyophilized liposomal formulations containing sucrose-lipid 
ratio 2.5:1 kept at –20 °C were 6.73 ± 0.8 (n = 5) and 6.58 ± 
0.5 (n = 5), respectively. The pH values of the lyophilized and International Journal of Nanomedicine 2007:2(2) 216
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the reconstituted lyophilized niosomal formulations contain-
ing sucrose-lipid ratio 2.5:1 kept at –20 °C was 6.77 ± 0.3 
(n = 5) and 6.72 ± 0.3 (n = 5), respectively. Those (lyophilized 
niosomes) kept at 4 °C had the value 6.78 ± 0.7 (n = 5). 
Size distribution of the formulations was done by zeta 
sizer (nanosizer) before and after storage. The zeta potentials 
were given in Table 2. L1 and L2 gave similar values. N1, 
N2, and N3 also gave similar zeta potentials. Again, L3 and 
N4 had similar values. The representatives of each type, L1, 
N1, and L3 are given in Table 2. Since the zeta potentials 
of the formulations with and without drug varied, they were 
mentioned in the table. Zeta potentials of the formulations 
without drug were strongly negative whereas, those with 
drug became less negative. In case of N1, N2, and N3, the 
formulations even showed positive values. No change in zeta 
potential was detected before and after the storage of the 
formulations at the different temperatures. The polydispersity 
index before and after storage for three months was measured. 
The values were 0.824 ± 0.17 (n = 3) (reconstituted lyophi-
lized) and 0.532 ± 0.19 (n = 3) (lyophilized), and 0.368 ± 
0.026 (n = 3) (reconstituted lyophilized) and 0.335 ± 0.063 
(n = 3) (lyophilized) of the liposomal formulations before 
and after storage at –20 °C respectively. In case of the nio-
somal formulations, the values were 0.757 ± 0.15 (n = 3) 
(reconstituted lyophilized), 0.645 ± 0.08 (n = 3) (lyophilized) 
and 0.718 ± 0.022 (n = 3) (reconstituted lyophilized), 0.633 
± 0.05 (n = 3) (lyophilized) before and after the storage at 
–20 °C, respectively. Niosomes (lyophilized) stored at 4 °C 
had the values 0.666 ± 0.07 and 0.598 ± 0.02 before and after 
the storage at 4 °C respectively.
Figures 2, 3, and 4 show the IR spectrum of the drug 
acyclovir, physical mixture of cholesterol and soya lecithin 
(wt. ratio = 1:1), and physical mixture of cholesterol, soya 
lecithin with acyclovir (wt. ratio = 1:1:1) respectively. 
No predominant drug interaction was detected. Although, 
there were some mild interactions in the wave number 
3600–3200 cm–1 and 1500–800 cm–1. The region 3600–3200 
cm–1 is a stretching region of the functional group N-H, C-H 
Figure 1 Vesicular fusion and drug crystallization of a formulation with sucrose to lipid ratio 1:1. 
Table 2 Zeta potential (ZP) data of different formulations
 ZP(mV)
  Without drug  With drug
L1,SPC:CHa  –8.413 –1.972
N1,SPC:CH:Span 20b  –7.018 1.439
L3, SPC:CH:PEG 400c  –17.34 –11.86
Note: Measuring temperature = 25 °C; aSPC:CH = 131.57:28.71 (μmole); bSpan 20 
= 44.48 μmole; cPEG 400 = 84.37 μmole; dAmount of drug, acyclovir taken for each 
of the formulations with drug = 22.2 μmole.
Formulation 
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of aromatic ring (3100–3000 cm–1), O-H (3200 cm–1) and C-H 
of alkenes (3100–3000 cm–1) and C-H of alkane (∼3000 cm–1). 
The region 1500–800 cm–1 is the stretching region of the 
functional group C-OH of alcohol (1400–1075 cm–1). In the 
region 1500–800 cm–1, the weak drug interaction was noticed 
at 1383.33, 985.69, and 899.71 cm–1. The FTIR study of the 
niosomes after freeze drying (Figure 5), after the storage 
at 4 °C (the lyophilized niosomes) (Figure 6), lyophilized 
niosome stored at –20 °C (Figure 7) and the reconstituted 
lyophilized niosomes stored at –20 °C (Figure 8) for three 
months were done to observe any chemical interaction 
between the drug and the excipients. No new different changes 
in the spectrum were noticed after storing them at different 
temperatures. This indicates that at those storage temperatures 
the formulations were stable. No change was noticed in case 
of liposomes stored at –20 °C (data not shown).
When the reconstituted lyophilized and the lyophilized 
formulations were compared, it was noticed that all the 
formulations stored at –20 °C and the lyophilized niosomes 
stored at 4 °C did not vary LP considerably as compared with 
the fresh preparations (Figure 9).
When vesicular size and frequency distribution were 
studied, it was seen that the maximum frequency distribution 
(about 35%) was of the vesicles having sizes of 100 nm 
and below (Figures 10 and 11). Sizes of remaining vesicles 
were within the size range up to 600 nm with an average 
frequency percentage of about 5%. The maximum percentage 
of vesicles was within a size range of 100 nm. Figures 12, 13, 
and 14 are SEM photographs of N1, L1, and L3 formulations. 
The vesicle sizes were less than 500 nm in diameter (in N1 
and L1), whereas L3 had larger vesicles.
When the in vitro release of acyclovir was studied from 
the liposomes and the niosomes, it was found that about 90% 
release of drug was obtained from the liposomal formula-
tion (L1) in 150 min whereas about 50% drug release was 
achieved in case of the niosomal formulation (N1) in about 
200 min (Figure 15). About 95% release was monitored from 
N1 only after 7 h (data not shown).
Discussion
Colloidal nanovesicular delivery systems of acyclovir were 
tried here. Various formulations were prepared with various 
combinations of cholesterol and soya L-α-lecithin in one 
case (formulations, L1, L2, and L3) and cholesterol and 
span 20 in the other case (N2, N3, and N4). In case of L3 
formulation, PEG 400 was used along with the cholesterol 
and soya L-α-lecithin. In N1, soya L-α-lecithin, cholesterol 
and span 20 were used.
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Figure 9 Lipid peroxidation (in micro M) of different formulations. Data show 
mean± SD (n = 5). l1(reconstituted lyophilized) and l2(lyophilized) are the fresh 
liposomal and n1(reconstituted lyophilized),n2 (lyophilized), and n3(reconstituted 
lyophilized niosomes kept at 4 °C for 1 h) are the fresh (not stored except n3) 
niosomal formulations. Again L1 (reconstituted lyophilized liposomes stored 
at –20 °C), L2 (lyophilized liposomes stored at –20 °C) and N1 (reconsti-
tuted lyophilized niosomes stored at –20 °C), N2 (lyophilized niosomes stored 
at –20 °C) and N3 (reconstituted lyophilized niosomes stored at 4 °C ) are those 
formulations stored at different temperatures as mentioned.
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Figure 10 Size distribution data of N1 formulation using image analyzer.
Before the development of the formulations, FTIR studies 
were conducted to determine the drug-excipient interactions. 
Drug-excipient interaction study is one of the most important 
parameters, which depicts much information including the 
stability of formulations, drug release from them and drug 
availability patterns (Mukherjee et al 2005). The results sug-
gest that the weak bond formations took place between –OH 
group of Span 20 and/or cholesterol with a nitrogen atom 
present in the purine ring of the drug. Minor variation of the 
peak when compared with the cholesterol standard indicates 
that the interaction was a mild one. When spectrum of the 
various ﬁ  gures were compared in the wave number region 
between 3600 cm–1 and 3200 cm–1, it was found that there 
were some weak interactions between the drug and phos-
pholipids. There may be a formation of hydrogen bonds or 
some other weak bonds due to van der Waal forces, dipole 
moment, etc amongst the functional groups N-H, C=O, -OH, 
-NH2 of the drug and phospholipid moieties. However, these 
interactions may favor the formation of vesicular shape, 
stabilizing the structures, and slower release of drug (Zhao 
and Feng 2005). Among the nonionic surfactant esters, Span 
20 has C11 saturated alkyl chain which is believed to assist 
in the formation of smaller vesicles because of the smaller 
alkyl chain of Span 20 as compared with the other varieties 
(Hao et al 2002). This has once again been proved to be true 
since smaller vesicles were obtained in N1 and N2 (<500 
nm). Again along with the same composition of N2 in N4 
when PEG 400 was used, the vesicle size became larger 
(1000–1500 nm), although the drug loading did not improve. 
PEG in the formulation membranes generally occupies an 
additional surface hydration thickness. It thus produced 
the size of vesicles larger with a size distribution between International Journal of Nanomedicine 2007:2(2) 222
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Figure 11 Size distribution data of the formulation N1. Here “b1, b2, b3” and “b11, b22, b33” were the various size range between 100 nm and 1 μm. 
Figure 12 Photograph of nonionic vesicular dispersions using scanning electron microscopy.International Journal of Nanomedicine 2007:2(2) 223
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Figure 14 Scanning electron microscopic photograph of liposome dispersion taking from supernatant of the formulation before centrifugation.  
Figure 13 Photograph of distribution of liposome vesicles using scanning electron microscopy.International Journal of Nanomedicine 2007:2(2) 224
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1000–1500 nm. However, PEG 400 was found to increase 
the stability of the formulations by preventing aggregation 
of vesicles. This was further conﬁ  rmed by SEM study. Al-
though the other physico-chemical data of this formulation 
were not shown as it had larger size. The vesicular size and 
frequency distribution demonstrated that about 35% of the 
vesicles having sizes within 100 nm and all the niosomes 
were in nano-dimension. 
Keeping the amount of soya-lecithin ﬁ  xed (100 mg), 
different formulations (L1, L2, and L3) were prepared by 
varying the amount of cholesterol. It was found that drug 
loading in L1 was about 8% (Table 1). When the amount 
of cholesterol was decreased in L2 as compared with L1, 
the drug loadings did not vary a lot. But there seemed to be 
an inﬂ  uence of cholesterol content on drug loading in case 
of the formulations with cholesterol and span 20. With the 
decreasing amount of cholesterol, drug loading substantially 
decreased in those formulations. One important observation 
was that with a ﬁ  xed amount of cholesterol, addition of PEG 
reduced the drug loading too. The maximum drug loading 
was noticed in N1 among the prepared formulations. 
When zeta potential was studied to understand the sur-
face charges of the vesicles (Table 2), it was noticed that 
acyclovir reduces the highly negative surface charges to less 
negative values and the addition of nonionic surfactant made 
it positive. This may be due to the cationic charge present 
with the drug and the drug in presence of Span 20 might have 
interacted and neutralized the surface charges existed on the 
formulation surface. Extra positive charge generated on the 
formulation surface in the process was detected. 
Nonlyophilized samples were found to be degraded and 
conglomerated along with the lyophilized samples without 
sucrose. But the samples with sucrose-lipid ratio 2.5:1, were 
found to maintain the physicochemical stabilities at –20 °C 
and in some cases (niosomes) at 4 °C. The formulation with 
sucrose to lipid ratio by weight 2.5:1 showed persistent result 
in terms of stability, preventing conglomeration and main-
taining size and shape at the temperatures mentioned.
Lipid peroxidation causes the instability of the constitu-
ent phospholipid, which ultimately leads to the degradation 
of the formulations. When the reconstituted lyophilized and 
lyophilized formulations were compared, it was noticed 
that all the formulations stored at –20 °C and lyophilized 
niosomes stored at 4 °C did not vary LP considerably as com-
pared with the fresh preparations. This indicates the stability 
of the formulations from lipid degradation also.
When the in vitro release of acyclovir was studied from 
the liposomes and the niosomes, it was found that about 90% 
Release of Acyclovir from Liposome and Niosome
formulations
C
u
m
u
l
a
t
i
v
e
 
%
 
d
r
u
g
 
r
e
l
e
a
s
e
Time (min.)
Niosome
formulation
Liposome
formulation
0
0
10
20
30
40
50
60
70
80
90
100
100 200 300 400 500 600
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release of drug was obtained from the ﬁ  rst type formulation 
(L1) in 150 min whereas about 50% drug release was 
achieved in case of the niosomal formulation (N1) in about 
200 min. The trend was similar in case of the other liposomal 
and niosomal formulations. This could be because niosomes 
contain span 20, which has been reported to interact with 
amino group (Hao et al 2002), which is present in acyclovir. 
Thus, this interaction might hold a substantial amount of drug 
(ie, about 50%) and released the drug molecules slowly from 
the niosomal formulations. About 95% drug release was 
monitored from N1 only after 7 h.
Conclusion
The results suggest that acyclovir released for a prolonged 
period of time from the niosomal formulation (N1). Since 
they had nano-dimensions, longer residence time in systemic 
circulation could help them reaching the target tissues. 
However, further studies regarding in vivo experiments are 
warranted.
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